Liquidata Share/ETF/Trust Analysis
Portfolio Holdings Detail for ISIN IE00BF4RFH31
| Stock Name / Fund | iShares MSCI World Small Cap UCITS ETF USD (Acc) |
| Issuer | Blackrock |
| Entity holding fund | iShares III Public Limited Company |
| Entity Type | Umbrella investment company with variable capital and having segregated liability between its funds |
| Entity LEI | 549300PZLRJB7M8H1057 |
| ETF Ticker | WSML(USD) LSE |
| ETF Ticker | WLDS(GBP) LSE |
| ETF Ticker | IUSN(EUR) F |
| ETF Ticker | IUSN.DE(EUR) CXE |
| ETF Ticker | WLDS.LS(GBP) CXE |
| ETF Ticker | WSML.LS(USD) CXE |
| ETF Ticker | WSML.L(GBP) LSE |
| ETF Ticker | WLDS.L(GBP) LSE |
Holdings detail for DNLI
| Stock Name | Denali Therapeutics Inc |
| Ticker | DNLI(USD) NASDAQ |
| TYPE | Common Stock |
| Country | USA |
| ISIN | US24823R1059 |
| LEI | 549300ZTQ2HO18L3Q830 |
Show aggregate DNLI holdings
News associated with DNLI
- Financial Survey: Denali Therapeutics (NASDAQ:DNLI) & Celcuity (NASDAQ:CELC)
- Denali Therapeutics (NASDAQ:DNLI – Get Free Report) and Celcuity (NASDAQ:CELC – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations. Analyst Ratings This is a summary of current ratings […] - 2025-09-17 02:12:56
- Denali Therapeutics (NASDAQ:DNLI) Receives “Overweight” Rating from Cantor Fitzgerald
- Cantor Fitzgerald restated their overweight rating on shares of Denali Therapeutics (NASDAQ:DNLI – Free Report) in a research note released on Monday morning,Benzinga reports. Other research analysts have also recently issued reports about the company. TD Cowen raised Denali Therapeutics to a “strong-buy” rating in a report on Monday, July 28th. Morgan Stanley dropped their […] - 2025-09-09 02:50:44
- Denali Therapeutics (NASDAQ:DNLI) Upgraded at TD Cowen
- Denali Therapeutics (NASDAQ:DNLI – Get Free Report) was upgraded by TD Cowen to a “strong-buy” rating in a research note issued to investors on Monday,Zacks.com reports. DNLI has been the subject of a number of other reports. Cantor Fitzgerald raised shares of Denali Therapeutics from a “neutral” rating to an “overweight” rating in a research […] - 2025-07-30 02:20:44
- Denali Therapeutics Inc. (NASDAQ:DNLI) Given Average Rating of “Buy” by Brokerages
- Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) has received an average rating of “Buy” from the seventeen analysts that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating, fourteen have issued a buy rating and two have given a strong buy rating to the company. […] - 2025-07-29 02:30:59
- New York State Common Retirement Fund Has $955,000 Stake in Denali Therapeutics Inc. (NASDAQ:DNLI)
- New York State Common Retirement Fund decreased its position in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 51.5% in the first quarter, HoldingsChannel reports. The firm owned 70,240 shares of the company’s stock after selling 74,484 shares during the period. New York State Common Retirement Fund’s holdings in Denali Therapeutics were worth $955,000 at […] - 2025-07-25 04:56:54
- DekaBank Deutsche Girozentrale Raises Position in Denali Therapeutics Inc. (NASDAQ:DNLI)
- DekaBank Deutsche Girozentrale raised its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 7.4% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 64,210 shares of the company’s stock after acquiring an additional 4,410 shares during the quarter. DekaBank Deutsche Girozentrale’s holdings in Denali Therapeutics were worth $935,000 as of its most […] - 2025-07-14 06:44:51
- Denali Therapeutics Inc. (NASDAQ:DNLI) CEO Ryan J. Watts Sells 495,282 Shares
- Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) CEO Ryan J. Watts sold 495,282 shares of Denali Therapeutics stock in a transaction on Wednesday, July 9th. The shares were sold at an average price of $15.00, for a total value of $7,429,230.00. Following the completion of the transaction, the chief executive officer owned 253,071 shares […] - 2025-07-14 05:10:49
- LABU's Holdings Imply 58% Gain Potential
- Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-07-10 07:59:01
- Denali Therapeutics Inc. (NASDAQ:DNLI) Receives $33.71 Average PT from Brokerages
- Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) has earned an average recommendation of “Buy” from the seventeen research firms that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold rating, fourteen have issued a buy rating and two have given a strong buy rating […] - 2025-06-12 02:28:50
- Analysts Anticipate VB To Hit $270
- Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-06-09 08:43:39
- Two Sigma Advisers LP Acquires Shares of 15,100 Denali Therapeutics Inc. (NASDAQ:DNLI)
- Two Sigma Advisers LP acquired a new stake in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 15,100 shares of the company’s stock, valued at approximately $308,000. Other hedge funds also recently bought […] - 2025-06-06 05:12:49
- Squarepoint Ops LLC Purchases 14,896 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)
- Squarepoint Ops LLC grew its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 44.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 48,619 shares of the company’s stock after buying an additional 14,896 shares during the quarter. Squarepoint […] - 2025-06-01 05:31:11
- MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Purchases 3,411 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)
- MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 4.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 85,075 shares of the company’s stock after purchasing an additional 3,411 shares during […] - 2025-05-23 06:26:52
- Janus Henderson Group PLC Purchases 7,900 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)
- Janus Henderson Group PLC grew its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 15.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 60,028 shares of the company’s stock after purchasing an additional 7,900 shares during the quarter. Janus Henderson Group PLC’s […] - 2025-05-23 05:26:51
- Bank of America Cuts Denali Therapeutics (NASDAQ:DNLI) Price Target to $27.00
- Denali Therapeutics (NASDAQ:DNLI – Get Free Report) had its price objective reduced by research analysts at Bank of America from $28.00 to $27.00 in a report issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. Bank of America‘s price objective suggests a potential upside of 88.94% from the stock’s current […] - 2025-05-21 02:56:58
- Deutsche Bank AG Buys 37,907 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)
- Deutsche Bank AG boosted its position in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 15.8% during the 4th quarter, Holdings Channel.com reports. The firm owned 277,853 shares of the company’s stock after purchasing an additional 37,907 shares during the period. Deutsche Bank AG’s holdings in Denali Therapeutics were worth $5,663,000 as of its most […] - 2025-05-19 05:06:53
- Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Bought by Northern Trust Corp
- Northern Trust Corp grew its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 10.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,201,518 shares of the company’s stock after acquiring an additional 115,876 shares during the […] - 2025-05-13 05:28:54
- Denali Therapeutics (NASDAQ:DNLI) Trading Down 10.1% Following Weak Earnings
- Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report)’s stock price was down 10.1% on Tuesday following a dissappointing earnings announcement. The stock traded as low as $14.41 and last traded at $14.38. Approximately 525,609 shares changed hands during trading, a decline of 52% from the average daily volume of 1,084,610 shares. The stock had previously […] - 2025-05-08 03:08:47
- Dimensional Fund Advisors LP Has $37.81 Million Stock Position in Denali Therapeutics Inc. (NASDAQ:DNLI)
- Dimensional Fund Advisors LP lifted its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 19.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,855,036 shares of the company’s stock after purchasing an additional 295,594 shares during the period. […] - 2025-05-05 05:20:52
- Sterling Capital Management LLC Has $36,000 Stake in Denali Therapeutics Inc. (NASDAQ:DNLI)
- Sterling Capital Management LLC raised its stake in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 589.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,773 shares of the company’s stock after purchasing an additional 1,516 shares during the quarter. Sterling […] - 2025-04-25 05:34:52
- Franklin Resources Inc. Decreases Position in Denali Therapeutics Inc. (NASDAQ:DNLI)
- Franklin Resources Inc. reduced its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 6.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 74,862 shares of the company’s stock after selling 5,179 shares during the period. […] - 2025-04-15 04:56:57
- Pictet Asset Management Holding SA Grows Stock Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI)
- Pictet Asset Management Holding SA raised its stake in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 17.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 19,356 shares of the company’s stock after buying an additional 2,806 shares during the […] - 2025-04-10 05:37:07
- Sei Investments Co. Lowers Stock Position in Denali Therapeutics Inc. (NASDAQ:DNLI)
- Sei Investments Co. decreased its stake in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 8.5% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 24,047 shares of the company’s stock after selling 2,229 shares during the quarter. Sei Investments Co.’s holdings in Denali Therapeutics were worth $490,000 at the end of the […] - 2025-04-10 04:18:49
- 1,065,608 Shares in Denali Therapeutics Inc. (NASDAQ:DNLI) Purchased by Norges Bank
- Norges Bank bought a new position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm bought 1,065,608 shares of the company’s stock, valued at approximately $21,717,000. Several other hedge funds also recently made changes to their […] - 2025-04-07 04:51:10
- Schroder Investment Management Group Has $5.02 Million Stock Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI)
- Schroder Investment Management Group increased its position in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 94.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 247,800 shares of the company’s stock after purchasing an additional 120,494 shares during the […] - 2025-04-06 05:29:07
- Corebridge Financial Inc. Sells 4,665 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)
- Corebridge Financial Inc. lowered its position in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 7.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 61,800 shares of the company’s stock after selling 4,665 shares during the quarter. […] - 2025-04-04 05:09:15
- American Century Companies Inc. Buys 29,155 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)
- American Century Companies Inc. raised its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 6.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 480,529 shares of the company’s stock after buying an additional 29,155 shares during the period. American Century Companies Inc.’s […] - 2025-04-03 04:32:51
- Teacher Retirement System of Texas Purchases 5,987 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI)
- Teacher Retirement System of Texas grew its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 18.6% in the 4th quarter, Holdings Channel reports. The fund owned 38,178 shares of the company’s stock after buying an additional 5,987 shares during the period. Teacher Retirement System of Texas’ holdings in Denali Therapeutics were […] - 2025-03-31 05:00:58
- Cibc World Markets Corp Purchases Shares of 11,633 Denali Therapeutics Inc. (NASDAQ:DNLI)
- Cibc World Markets Corp acquired a new position in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 11,633 shares of the company’s stock, valued at approximately $237,000. Other large investors have also modified their holdings […] - 2025-03-26 06:09:01
- Denali Therapeutics Inc. (NASDAQ:DNLI) Given Consensus Recommendation of “Moderate Buy” by Brokerages
- Shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the eighteen research firms that are covering the company, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation, fifteen have assigned a buy recommendation and one has assigned a strong buy […] - 2025-03-26 04:26:42
iShares MSCI World Small Cap UCITS ETF USD (Acc) DNLI holdings
| Date | Number of DNLI Shares Held | Base Market Value of DNLI Shares | Local Market Value of DNLI Shares | Change in DNLI Shares Held | Change in DNLI Base Value | Current Price per DNLI Share Held | Previous Price per DNLI Share Held |
|---|
| 2025-10-15 (Wednesday) | 102,936 | USD 1,678,886 | USD 1,678,886 | | | | |
| 2025-10-10 (Friday) | 102,303 | USD 1,572,397 | USD 1,572,397 | | | | |
| 2025-10-08 (Wednesday) | 102,303 | USD 1,601,042 | USD 1,601,042 | | | | |
| 2025-10-07 (Tuesday) | 102,303 | USD 1,524,315 | USD 1,524,315 | 420 | USD -26,344 | USD 14.9 | USD 15.22 |
| 2025-10-06 (Monday) | 101,883 | USD 1,550,659 | USD 1,550,659 | 0 | USD -20,377 | USD 15.22 | USD 15.42 |
| 2025-10-03 (Friday) | 101,883 | USD 1,571,036 | USD 1,571,036 | 0 | USD 22,414 | USD 15.42 | USD 15.2 |
| 2025-10-02 (Thursday) | 101,883 | USD 1,548,622 | USD 1,548,622 | 0 | USD 29,546 | USD 15.2 | USD 14.91 |
| 2025-10-01 (Wednesday) | 101,883 | USD 1,519,076 | USD 1,519,076 | 0 | USD 39,735 | USD 14.91 | USD 14.52 |
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdingsShare Trades of DNLI by Blackrock for IE00BF4RFH31
Show aggregate share trades of DNLI| Date | Action | Quantity | Market High | Market Low | Likely Trade Price | Likely Trade Value (Profit/Loss) | Average Price previous trades |
|---|
| 2025-10-07 | BUY | 420 | | | 14.900* | | 17.78 |
| 2025-09-08 | SELL | -840 | | | 15.500* | | 17.97 Profit of 15,092 on sale |
| 2025-08-15 | BUY | 420 | | | 14.700* | | 17.99 |
| 2025-08-07 | BUY | 1,254 | | | 14.230* | | 18.03 |
| 2025-07-29 | BUY | 420 | | | 13.610* | | 18.18 |
| 2025-07-14 | BUY | 840 | | | 14.690* | | 18.35 |
| 2025-06-30 | BUY | 840 | | | 13.990* | | 18.53 |
| 2025-06-25 | BUY | 1,260 | | | 14.450* | | 18.61 |
| 2025-06-20 | SELL | -212 | | | 13.890* | | 18.71 Profit of 3,967 on sale |
| 2025-06-12 | SELL | -1,688 | | | 14.925* | | 18.91 Profit of 31,914 on sale |
| 2025-06-02 | BUY | 639 | | | 13.960* | | 19.18 |
| 2025-05-28 | BUY | 424 | | | 13.040* | | 19.33 |
| 2025-05-14 | BUY | 211 | | | 13.960* | | 19.82 |
| 2025-05-13 | BUY | 422 | | | 14.260* | | 19.87 |
| 2025-05-07 | BUY | 630 | | | 14.320* | | 20.07 |
| 2025-04-28 | BUY | 210 | | | 16.250* | | 20.35 |
| 2025-04-16 | BUY | 2,756 | | | 12.550* | | 20.90 |
| 2025-04-14 | BUY | 422 | | | 13.270* | | 21.07 |
| 2025-04-08 | SELL | -426 | | | 11.470* | | 21.47 Profit of 9,147 on sale |
| 2025-04-04 | SELL | -426 | | | 11.780* | | 21.70 Profit of 9,245 on sale |
| 2025-03-28 | BUY | 2,120 | | | 14.780* | | 22.10 |
| 2025-03-24 | BUY | 16,618 | | | 14.760* | | 22.51 |
| 2025-03-12 | SELL | -348 | | | 15.950* | | 23.38 Profit of 8,138 on sale |
| 2025-03-04 | SELL | -346 | | | 15.950* | | 23.98 Profit of 8,296 on sale |
| 2025-02-26 | SELL | -684 | | | 18.890* | | 24.42 Profit of 16,705 on sale |
| 2025-02-13 | BUY | 173 | | | 21.310* | | 25.00 |
| 2025-02-12 | BUY | 692 | | | 20.820* | | 25.09 |
| 2025-01-27 | BUY | 171 | | | 23.190* | | 25.86 |
| 2025-01-23 | BUY | 171 | | | 23.280* | | 26.03 |
| 2024-12-09 | BUY | 6,192 | | | 24.960* | | 26.28 |
| 2024-12-04 | BUY | 342 | | | 23.700* | | 26.52 |
| 2024-12-03 | BUY | 513 | | | 23.890* | | 26.62 |
| 2024-11-19 | BUY | 1,026 | | | 24.340* | | 27.64 |
| 2024-11-18 | BUY | 340 | | | 24.180* | | 27.84 |
| 2024-11-12 | BUY | 676 | | | 29.890* | | 27.71 |
| 2024-11-11 | BUY | 169 | | | 31.580* | | 27.45 |
| 2024-11-07 | BUY | 845 | | | 29.600* | | 26.99 |
| 2024-10-23 | BUY | 338 | | | 26.080* | | 26.34 |
Market high and low price is on the date. * (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection
The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close
Shorting History of DNLI
| Date | Shorted Volume | Short Exempt Volume | Total Shares Traded | % Shorted |
|---|
| 2025-09-19 | 378,159 | 1,201 | 906,799 | 41.7% |
| 2025-09-18 | 267,705 | 7,938 | 845,210 | 31.7% |
| 2025-09-17 | 409,861 | 700 | 1,166,910 | 35.1% |
| 2025-09-16 | 391,495 | 300 | 1,419,697 | 27.6% |
| 2025-09-15 | 260,665 | 0 | 671,937 | 38.8% |
| 2025-09-12 | 206,570 | 0 | 814,137 | 25.4% |
| 2025-09-11 | 275,762 | 207 | 657,649 | 41.9% |
| 2025-09-10 | 329,334 | 0 | 769,460 | 42.8% |
| 2025-09-09 | 309,105 | 0 | 685,690 | 45.1% |
| 2025-09-08 | 379,188 | 58 | 1,067,132 | 35.5% |
| 2025-09-05 | 349,059 | 0 | 2,670,128 | 13.1% |
| 2025-09-04 | 280,937 | 11,807 | 555,931 | 50.5% |
| 2025-09-03 | 417,113 | 0 | 1,357,895 | 30.7% |
| 2025-09-02 | 422,885 | 5,205 | 3,059,398 | 13.8% |
| 2025-08-29 | 549,150 | 3 | 991,426 | 55.4% |
| 2025-08-28 | 543,279 | 750 | 1,001,438 | 54.2% |
| 2025-08-27 | 366,427 | 0 | 654,686 | 56.0% |
| 2025-08-26 | 644,048 | 0 | 1,095,696 | 58.8% |
| 2025-08-25 | 291,784 | 0 | 587,617 | 49.7% |
| 2025-08-22 | 312,554 | 200 | 1,397,371 | 22.4% |
| 2025-08-21 | 399,082 | 0 | 875,607 | 45.6% |
| 2025-08-20 | 326,184 | 0 | 625,317 | 52.2% |
| 2025-08-19 | 264,863 | 0 | 410,141 | 64.6% |
| 2025-08-18 | 309,669 | 0 | 516,163 | 60.0% |
| 2025-08-15 | 209,560 | 0 | 463,256 | 45.2% |
| 2025-08-14 | 332,064 | 232 | 818,152 | 40.6% |
| 2025-08-13 | 524,452 | 0 | 992,838 | 52.8% |
| 2025-08-12 | 325,318 | 1,582 | 713,957 | 45.6% |
| 2025-08-11 | 295,585 | 0 | 597,428 | 49.5% |
| 2025-08-08 | 698,451 | 0 | 1,028,935 | 67.9% |
| 2025-08-07 | 587,323 | 0 | 987,051 | 59.5% |
| 2025-08-06 | 756,413 | 0 | 1,219,503 | 62.0% |
| 2025-08-05 | 416,200 | 26,598 | 1,111,990 | 37.4% |
| 2025-08-04 | 474,241 | 500 | 928,766 | 51.1% |
| 2025-08-01 | 365,641 | 0 | 787,315 | 46.4% |
| 2025-07-31 | 376,072 | 66 | 896,403 | 42.0% |
| 2025-07-30 | 509,961 | 8 | 956,417 | 53.3% |
| 2025-07-29 | 282,888 | 12 | 622,537 | 45.4% |
| 2025-07-28 | 292,351 | 0 | 614,152 | 47.6% |
| 2025-07-25 | 234,267 | 0 | 458,041 | 51.1% |
| 2025-07-24 | 289,899 | 84 | 723,176 | 40.1% |
| 2025-07-23 | 345,904 | 711 | 676,129 | 51.2% |
| 2025-07-22 | 228,079 | 98 | 411,315 | 55.5% |
| 2025-07-21 | 237,820 | 0 | 416,453 | 57.1% |
| 2025-07-18 | 226,511 | 0 | 419,959 | 53.9% |
The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.
Back to Listing
Disclaimer
All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.